HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trialsDaniel I. Swerdlow, Rudi G. J. Westendorp, David Preiss et al.|The Lancet|2014Cited by 709
Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort ConsortiumNicolas Wentzensen, Lynne R. Wilkens, Lesley M. Butler et al.|Journal of Clinical Oncology|2016Cited by 517
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation studyAmand F. Schmidt, Andrzej Pająk, Daniel I. Swerdlow et al.|The Lancet Diabetes & Endocrinology|2016Cited by 390
Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC)N. E. Allen, Rudolf Kaaks, Timothy J. Key et al.|Endocrine Related Cancer|2008Cited by 270
Hormonal, Metabolic, and Inflammatory Profiles and Endometrial Cancer Risk Within the EPIC Cohort—A Factor AnalysisLaure Dossus, Rudolf Kaaks, Annekatrin Lukanova et al.|American Journal of Epidemiology|2013Cited by 157